Claudio Scavelli
Gallipoli, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Journal: Tumori
Published: April 11, 2022
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Journal: Tumori
Published: December 19, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Journal: Journal of translational medicine
Published: May 30, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: January 08, 2019
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: October 24, 2018
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Journal: Breast care (Basel, Switzerland)
Published: July 23, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: April 02, 2018
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Journal: Breast (Edinburgh, Scotland)
Published: April 10, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Journal: Breast cancer research and treatment
Published: March 19, 2017
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Journal: Oncotarget
Published: February 28, 2016
Long-term efficacy and safety of a third-line treatment with eribulin plus trastuzumab in a young breast cancer patient.
Journal: Future oncology (London, England)
Published: December 05, 2014
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Journal: Medical oncology (Northwood, London, England)
Published: February 01, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026